公开(公告)号：US20250115665A1

公开(公告)日：2025-04-10

申请号：US18833261

申请日：2023-01-27

Applicant: GENMAB A/S

Inventor： Christopher W. L. CHIU ,  Minh H. DINH ,  Mariana C. STIRNER ,  Iliana E. SZAFER-GLUSMAN

IPC: C07K16/28 ,  A61K31/454 ,  A61K31/519 ,  A61K39/00 ,  A61P35/00

Abstract: Provided are methods of clinical treatment of Diffuse Large B-cell Lymphoma (for example, relapsed and/or refractory Diffuse Large B-cell Lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with lenalidomide or ibrutinib and lenalidomide.

公开(公告)号：US12247065B2

公开(公告)日：2025-03-11

申请号：US17253286

申请日：2019-06-24

Applicant: GENMAB A/S

Inventor： Richard Hibbert ,  Rob De Jong ,  Aran Frank Labrijn ,  Arnout Gerritsen ,  Janine Schuurman ,  Paul Parren

IPC: C07K16/00 ,  C07K1/18 ,  C07K1/22

Abstract: The present invention relates to a method for controlling the composition of a mixture of two or more different antibodies, such as tow or more different monoclonal antibodies, using chromatography. The mixture is for use as a drug product and the method includes a controlled downstream process for the production of a predetermined ratio of the two or more different antibodies.

公开(公告)号：US20240383982A1

公开(公告)日：2024-11-21

申请号：US18289654

申请日：2022-05-09

Applicant: GENMAB A/S

Inventor： Martin SAHLIN ,  Abdallah ABDULRAHMAN ,  Jesse COE ,  Charles ABADIE

IPC: C07K16/28 ,  A61K47/18 ,  A61K47/22 ,  A61P35/00

Abstract: The present invention relates to pharmaceutical compositions and unit dosage forms comprising antibodies binding to B7H4 and CD3. The invention further provides a use of the pharmaceutical compositions and unit dosage forms for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US12115227B2

公开(公告)日：2024-10-15

申请号：US16069391

申请日：2017-01-13

Applicant: GENMAB A/S

Inventor： Lene Schantz Harlow ,  Timothy Warren Paul ,  Brendan M. Mayhugh ,  Kelly Ann Roby ,  Gregory Allan Sacha ,  Xiaona Jing ,  Andrew Hagarman ,  Cale Halbleib

IPC: A61K39/395 ,  A61K9/00 ,  A61K9/19 ,  A61K38/07 ,  A61K47/18 ,  A61K47/26 ,  A61K47/68 ,  A61K47/69 ,  C07K16/28 ,  A61K39/00

CPC classification number: A61K47/6849 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/07 ,  A61K39/39591 ,  A61K47/183 ,  A61K47/26 ,  A61K47/6803 ,  A61K47/6811 ,  A61K47/6921 ,  C07K16/2863 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2317/73

Abstract: Disclosed herein are surfactant free antibody and antibody-drug-conjugate (ADC) formulations for anti-AXL antibodies and ADCs, including aqueous formulations, lyophilized formulations, and reconstituted formulations, as well as related processes and uses. The formulations are particularly suitable for an anti-AXL ADC based on an auristatin or DM1 derivative or other similarly hydrophobic drugs. Some formulations comprise histidine and mannitol.

公开(公告)号：US20240228662A9

公开(公告)日：2024-07-11

申请号：US18235550

申请日：2023-08-18

Applicant: GENMAB A/S

Inventor： Michel DE WEERS ,  Yvo GRAUS ,  Judith OPRINS ,  Paul PARREN ,  Jan VAN DE WINKEL ,  Martine VAN VUGT

IPC: C07K16/40 ,  A61K39/395 ,  A61K49/00 ,  C07K14/705 ,  C07K16/28 ,  C12N5/10 ,  C12N15/63 ,  G01N33/566

CPC classification number: C07K16/40 ,  A61K39/3955 ,  A61K49/0004 ,  C07K14/70596 ,  C07K16/2896 ,  C12N5/10 ,  C12N15/63 ,  G01N33/566 ,  A61K2039/505 ,  C07K2317/34

Abstract: Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

公开(公告)号：US20240174761A1

公开(公告)日：2024-05-30

申请号：US18500673

申请日：2023-11-02

Applicant: GENMAB A/S

Inventor： Brian ELLIOTT ,  Rebecca X.M.S. VALENTIN ,  Daniela HOEHN ,  Marcia RIOS

IPC: C07K16/28 ,  A61P35/00 ,  A61K39/00

CPC classification number: C07K16/2887 ,  A61P35/00 ,  C07K16/2809 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31

Abstract: Provided are methods of clinical treatment of Richter's syndrome in human subjects using a bispecific antibody which binds to CD3 and CD20.

公开(公告)号：US20240109972A1

公开(公告)日：2024-04-04

申请号：US18038818

申请日：2021-12-07

Applicant: Genmab A/S ,  BioNTech SE

Inventor： Ugur SAHIN ,  Alexander MUIK ,  Ulf FORSSMANN ,  Maria JURE-KUNKEL ,  Manish GUPTA ,  Tahamtan AHMADI ,  Kathy AMIRI ,  Gaurav BAJAJ

IPC: C07K16/28 ,  A61K31/337 ,  A61K45/06 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61K31/337 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2827 ,  A61K2039/505

Abstract: The present invention provides combination therapy to reduce or prevent progression of a tumor or treating cancer in a subject. The combination therapy comprises administration of a binding agent that binds to human CD137 and to human PD-L1; and a taxane chemotherapeutic agent.

公开(公告)号：US20240091373A1

公开(公告)日：2024-03-21

申请号：US18065196

申请日：2022-12-13

Applicant: Genmab A/S

Inventor： Jesper VALBJØRN ,  Xiaona JING ,  Kelly Ann ROBY ,  Timothy Warren PAUL ,  Gregory Allan SACHA ,  Nathan Alan PEASE ,  Bodil WILLUMSEN

IPC: A61K47/68 ,  A61K9/19 ,  A61K39/395 ,  A61K47/22 ,  C07K16/36

CPC classification number: A61K47/6843 ,  A61K9/19 ,  A61K39/39591 ,  A61K47/22 ,  A61K47/6803 ,  A61K47/6889 ,  C07K16/36 ,  A61K47/183 ,  C07K2317/77

Abstract: Disclosed herein are surfactant free lyophilized formulations of antibody-drug conjugates (ADCs), such as anti-tissue factor ADCs, and reconstituted formulations, processes and uses thereof. The formulations are particularly suitable for an anti-TF ADC based on an auristatin derivative or other similarly hydrophobic drug. Typically, the excipients of the formulations comprise or consist of histidine, sucrose, trehalose, mannitol and glycine.

公开(公告)号：US20240084036A1

公开(公告)日：2024-03-14

申请号：US17972867

申请日：2022-10-25

Applicant: Genmab A/S

Inventor： Joost J. NEIJSSEN ,  Bart De Goeij ,  Edward Norbert Van Den Brink ,  Aran Frank Labrijn ,  Rene Hoet ,  Janine Schuurman ,  Paul Parren ,  Jan Van De Winkel

IPC: C07K16/30 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  C07K16/40 ,  G01N33/574

CPC classification number: C07K16/3076 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2863 ,  C07K16/40 ,  G01N33/5748 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/565 ,  C07K2317/71 ,  G01N2333/912

Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

公开(公告)号：US20240034812A1

公开(公告)日：2024-02-01

申请号：US18025203

申请日：2021-09-10

Applicant: GENMAB A/S

Inventor： Brian ELLIOTT ,  Tahamtan AHMADI ,  Christopher W.L. CHIU ,  Esther C.W. BREIJ ,  Ida HIEMSTRA ,  Maria N. JURE-KUNKEL

IPC: C07K16/46 ,  A61P35/00

CPC classification number: C07K16/468 ,  A61P35/00 ,  C07K2317/565 ,  C07K2317/31

Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).